DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Eating Disorders” report has been added to ResearchAndMarkets.com’s
offering.
This Market Spotlight report covers the Eating Disorders market,
comprising key marketed and pipeline drugs, clinical trials, upcoming
events, patent information, a 10-year disease prevalence forecast, and
licensing and acquisition deals, as well as presenting drug-specific
revenue forecasts
Key Takeaways
-
Worldwide, the report estimates that in 2017, there were approximately
35.6 million prevalent cases of eating disorders in females aged 10-19
years, including 3.0 million cases of anorexia nervosa, 11.6 million
cases of bulimia nervosa, and 14.3 million cases of binge eating
disorder. -
The author forecasts the number of prevalent cases of eating disorders
to increase to 38.1 million by 2026. Edgemont’s fluoxetine tablets and
Takeda’s Vyvanse are the only FDA-approved drugs for eating disorders.
These drugs are administered via the oral route, with Vyvanse also
available in an intranasal formulation. -
There are only three industry-sponsored drugs in active clinical
development for eating disorders, with two drugs in Phase II and one
in Phase III. -
Therapies in mid-to-late-stage development for eating disorders focus
on targets such as dopamine reuptake, norepinephrine (noradrenaline)
reuptake/transporter, opioid receptors, and ghrelin receptor. These
drugs are administered via the subcutaneous, oral, and intranasal
routes. -
The only high-impact upcoming event in the eating disorders space is
topline Phase II trial results for OPNT001. The overall likelihood of
approval of a Phase I psychiatry-other asset is 11.4%, and the average
probability a drug advances from Phase III is 80.8%. Drugs, on
average, take 9.2 years from Phase I to approval, compared to 8.8
years in the overall psychiatry space. -
There have been only three licensing and asset acquisition deals
involving eating disorders drugs during 2014-19. The distribution of
clinical trials across Phase I-IV indicates that the vast majority of
trials for eating disorders have been in the late phase of
development, with 91% of trials in Phase III, and only 9% in Phase II. -
The US has a substantial lead in the number of eating disorders
clinical trials globally, while Germany leads the major EU markets. -
Clinical trial activity in the eating disorders space is dominated by
completed trials. Takeda has the highest number of completed clinical
trials for eating disorders, with four trials. -
Takeda leads industry sponsors with the highest number of clinical
trials for eating disorders.
Key Topics Covered:
OVERVIEW
KEY TAKEAWAYS
DISEASE BACKGROUND
Subtypes
TREATMENT
Psychotherapy
Medications
EPIDEMIOLOGY
MARKETED DRUGS
PIPELINE DRUGS
RECENT EVENTS AND ANALYST OPINION
Dasotraline for Eating Disorders (July 25, 2018)
KEY UPCOMING EVENTS
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
PARENT PATENTS
REVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
BIBLIOGRAPHY
Prescription information
APPENDIX
For more information about this report visit https://www.researchandmarkets.com/r/x4d45q
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Mental
Health